Business & Investment

Fresh data show that paid South African viral variants undertake the effectiveness of the Reuters vaccine

© Reuters. File photo: The woman has a small bottle with the “Coronavirus COVID-19 Vaccine” sticker and the label of a medical syringe in front of the Novavax logo shown in this figure.


By Julie Steenhuysen

Chicago (Reuters)-Clinical trial data on two COVID-19 vaccines show that the first identified coronavirus variant in South Africa reduces its ability to protect against disease, as much as possible to a large number of people The scientists said they emphasized the need for early vaccination.

Vaccine from Novavax (NASDAQ :) Inc and Johnson & Johnson (NYSE :) are important future weapons to control death and hospitalization in a pandemic that has infected more than 101 million people and killed more than 2 million people worldwide. I was welcomed.

However, preliminary data released by both companies showed that the protective effect of COVID-19 was significantly reduced in South African study participants, who are still endemic with powerful new mutants.

“Clearly, mutants reduce the effect on vaccine efficacy,” Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said in a briefing. “We know we will be challenged.”

Novavax reported mid-stage study results Thursday, showing that the vaccine is overall 50% effective in preventing COVID-19 in South Africans.

This was compared to the late UK results where the vaccine was up to 89.3% effective in preventing COVID-19.

On Friday, J & J said a single shot of the coronavirus vaccine was overall 66% effective in a large trial across three continents.

However, there were major differences from region to region. In the United States, where the South African variant was first reported this week, efficacy reached 72%, while in South Africa a new variant known as B 1.351 accounted for 95% of COVID-19 cases. Reported at trial.

Another highly infectious variant, first discovered in the United Kingdom and now found in more than half of the US states, failed to circumvent the vaccine’s effectiveness over its South African counterpart.

But a new discovery is how a very effective vaccine Pfizer Inc (NYSE :) and partner BioNTech, and Moderna (NASDAQ :) Inc competes with new variants. The two vaccines showed approximately 95% efficacy in trials conducted primarily in the United States before new virus versions were identified in other countries.

“It’s another pandemic now,” said Dr. Danbaroch, a researcher at the Beth Israel Dikones Medical Center at Harvard Medical School, who helped develop the J & J vaccine.

Baruch said a wide variety of new mutants are now in circulation, including Brazil, South Africa, and even the United States, which are substantially resistant to vaccine-induced antibodies.

Pfizer CEO Albert Bourla said the new variant was “likely” likely to eventually invalidate the company’s vaccine.

“This isn’t the case yet … but I think it’s very likely that it will happen someday,” Bula told the World Economic Forum. Pharmaceutical companies are considering whether vaccines need to be changed to protect South African variants.

“Stop the hospital from falling into crisis”

Experts said that all four vaccines are still of great value in their ability to reduce severe COVID-19.

“The ultimate game is to stop death and prevent hospitals from falling into crisis. All of these vaccines, including those against South African variants, seem to do that virtually.” Said Dr. Amesh Adalja, an infectious disease expert.Johns Hopkins Center for Health Security

For example, the J & J vaccine was 89% effective in preventing serious illnesses in South Africa.

Dr. Paulstofels, Chief Scientific Officer at J & J, states that a type of immune system response called the T cell response plays a protective role and may help prevent serious illness. ..

“We knew it to some extent, but it’s also better and very sure that we can now see it in the clinic,” Stoffels said in an interview.

Nonetheless, Fauci said the reduced efficacy rate emphasized the need to closely track mutations and accelerate vaccination efforts before new, more dangerous mutations occur. It was.

“The best way to prevent further evolution of the virus is to prevent it from replicating, and we do that by vaccinating people as soon as possible,” Forch said.

Fresh data show that paid South African viral variants undertake the effectiveness of the Reuters vaccine Fresh data show that paid South African viral variants undertake the effectiveness of the Reuters vaccine

Back to top button